Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Mammaprint Stories

2012-09-13 02:28:30

AMSTERDAM and IRVINE, Calif., Sept. 13, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, announced today that they will present five posters on genomic research studies in breast cancer at the American Society of Clinical Oncology (ASCO) 2012 Breast Cancer Symposium. The meeting will be held from September 13-15, 2012 at the Marriott Marquis in San Francisco, California. Agendia's Symphony(TM) suite of molecular...

2012-08-29 10:23:21

IRVINE, Calif. and AMSTERDAM, Aug. 29, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, conducted one of its premiere thought leadership events, "Present and Future Trends in Breast Cancer Genomics," on Saturday, August 25, 2012. The event was held at The Westin Times Square Hotel in New York City and featured over 200 attendees that included leading medical oncologists, pathologists, surgeons and molecular biologists. The...

2012-08-20 02:31:39

IRVINE, Calif. and AMSTERDAM, Aug. 20, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that it has been granted the International Organization for Standardization (ISO) 13485 certification for all activities at their facilities in Irvine and Amsterdam. Agendia has been a leader in maintaining the highest quality standards and operating in compliance with FDA GMP QSR, CLIA, CAP, OSHA and the CE Mark as well...

2012-07-09 02:25:06

IRVINE, Calif. and AMSTERDAM, July 9, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced a key addition to their executive team with the appointment of Glen Fredenberg as CFO and Vice President of Finance. "It is a very exciting time with the recent launch of Agendia's Symphony suite of tests in an FFPE format as well as the ColoPrint recurrence test for stage II colon cancer prognosis and prediction," said...

2012-06-01 02:23:58

IRVINE, Calif. and AMSTERDAM, June 1, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery. ColoPrint provides a definitive relapse risk assessment for 100 percent of all stage II patients and eliminates the gray area of...

2012-03-22 12:40:21

Testing a breast cancer tumor for its genomic signature can help identify which patients will need adjuvant systemic therapy (additional chemotherapy) after surgery, and spare its use in those for whom it is not necessary, according to the results of a study to be presented to the 8th European Breast Cancer Conference (EBCC-8) today (Thursday). Dr. Sabine Linn, an Associate Professor of Medical Oncology at The Netherlands Cancer Institute, Amsterdam, The Netherlands, will say that this is the...

2012-03-22 06:25:37

IRVINE, Calif. and AMSTERDAM, March 22, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company, today announced that five-year follow-up data from the RASTER observational study indicates that its MammaPrint prognostic assay for breast cancer can help reduce adjuvant chemotherapy by 20 percent in patients deemed 'Low Risk.' From 2004 to 2006, the MircoarRAy PrognoSTics in Breast CancER study, known as RASTER, enrolled 427 women with primary breast carcinoma across...

2012-02-29 07:00:00

IRVINE, Calif. and AMSTERDAM, Feb. 29, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company, today announced that the company is a recipient of the 2011 Scrip Award for "Best Partnership" for its cooperative alliance between Agendia, AstraZeneca and the Netherlands Cancer Institute (NKI). This is the seventh annual competition to recognize and honor achievements throughout the pharmaceutical industry. The collaboration between Agendia, AstraZeneca and NKI...

2012-01-09 06:00:00

IRVINE, Calif. and AMSTERDAM, Jan. 9, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company, today announced that Peter C. Wulff has joined the company as Vice President of Finance and Chief Financial Officer. Wulff is responsible for all aspects of the company's global finance function. "We are very pleased to bring Peter Wulff onto our executive team as Vice President of Finance and Chief Financial Officer," said David Macdonald, CEO of Agendia. "Peter is...

2012-01-06 14:54:27

A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The advancement was made by researchers at Moffitt Cancer Center in Tampa, Fla., who published their study results in a recent issue of the Journal of the National Cancer Institute. According to corresponding author Dung-Tsa Chen, Ph.D., associate member with the Moffitt Biostatistics program, non-small cell lung...